ADC Therapeutics (ADCT) Payables (2019 - 2026)

ADC Therapeutics has disclosed Payables across 8 years of filings, most recently posting $5.3 million for Q1 2026.

• Payables for Q1 2026 came in at $5.3 million, down 66.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 million (down 66.04% YoY), and the FY2025 annual result was $9.2 million, down 49.11% from the prior year.
• Payables came in at $5.3 million for Q1 2026 at ADC Therapeutics, down from $9.2 million in the prior quarter.
• In the past five years, Payables ranged from a high of $18.0 million in Q4 2024 to a low of $5.3 million in Q1 2026.
• The 5-year median for Payables is $12.4 million (2022), against an average of $12.1 million.
• Across the five-year window, Payables gained 26.05% in 2023 and slumped 66.04% in 2026, its largest moves.
• ADC Therapeutics' Payables stood at $12.4 million in 2022, then gained by 26.05% to $15.6 million in 2023, then grew by 15.8% to $18.0 million in 2024, then tumbled by 49.11% to $9.2 million in 2025, then plunged by 42.29% to $5.3 million in 2026.
• The last three Payables figures came in at $5.3 million (Q1 2026), $9.2 million (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.